Search

Carotid ultrasound is a useful tool to detect plaque and measure carotid intimal-medial thickness (CIMT), which help identify asymptomatic patients at risk of cardiovascular events. However, the role of carotid ultrasound in stratifying risk in symptomatic patients has not been studied. We prospectively examined the hypothesis that in symptomatic patients undergoing exercise (or pharmacologic) stress testing (EST), CIMT and carotid plaque will improve the ability to identify patients with ≥50% coronary diameter stenosis. Mean and maximal CIMTs were measured in 50 symptomatic patients without known coronary artery disease (CAD) who were scheduled to undergo diagnostic angiography after EST with imaging. Pretest probability of CAD was calculated for each patient based on age, gender, and nature of symptoms. Fifty percent of patients were men, 32% were diabetic, 70% had hypertension, and 58% had dyslipidemia. CAD ≥50% was associated with CIMT in the >75th percentile (74% vs 44%, p = 0.047) and with presence of carotid plaque (96% vs 59%, p = 0.003). Of patients with an equivocal/negative EST result (n = 38), those with carotid plaque had a 46% (13 of 28) prevalence of significant CAD; in the smaller subset of patients without carotid plaque (n = 10), none had luminal stenosis ≥50% (p = 0.007). Pretest probability of CAD, presence of carotid plaque, moderately/severely abnormal EST result, and hypertension were independent predictors of significant CAD. In conclusion, carotid ultrasound appears to offer incremental value to EST in predicting presence or absence of ≥50% coronary diameter stenosis in symptomatic patients with equivocal/negative EST result. [Copyright &y& Elsevier]

In this retrospective case-control study, 8 of 223 consecutive patients (3.6%) treated with intravenous haloperidol developed torsades de pointes, and were compared with 41 patients randomly selected as controls. The likelihood of torsades de pointes associated with intravenous haloperidol is significantly greater in patients receiving > or = 35 mg over 24 hours or in those with a QTc interval of >500 ms, or both. [ABSTRACT FROM AUTHOR]

Numerous measures of left ventricular diastolic function are currently in clinical use. To determine which echo-Doppler left ventricular diastolic function measurements are most feasible in the clinical echocardiographic laboratory, the success rate, recording time taken by the sonographer, and inter-reader variability were calculated for transmitral valve inflow, pulmonary vein flow, tissue Doppler imaging, and color M-mode flow propagation velocity in 80 inpatients. [Copyright &y& Elsevier]

Transcatheter valve-in-valve implantation (ViV-TAVI) has evolved as an alternative to redo surgical valve replacement (redo-SAVR) for high-risk patients with aortic bioprosthetic valve (BPV) dysfunction. The differences in procedural success and outcomes in a large number of patients who underwent ViV-TAVI compared with redo-SAVR for aortic BPV dysfunction are not known. We conducted a meta-analysis of the previously reported studies to determine outcomes after ViV-TAVI and redo-SAVR. PubMed, MEDLINE, and Google Scholar databases were searched for studies that reported comparative outcomes of patients who underwent either ViV-TAVI or redo-SAVR. Four observational studies met the inclusion criteria, with a total of 489 patients, 227 of whom underwent ViV-TAVI and 262 underwent redo-SAVR. Thirty-day mortality was similar in 2 groups (5% vs 4%; odds ratio [OR] = 1.08, 95% confidence interval [CI] = 0.44 to 2.62) despite the higher operative risk in the ViV-TAVI cohort as evidenced by significantly higher EuroSCORE I or II. There were similar rates of stroke (2% vs 2%; OR = 1.00, 95% CI = 0.28 to 3.59), myocardial infarction (2% vs 1%; OR = 1.08, 95% CI = 0.27 to 4.33), and acute kidney injury requiring dialysis (7% vs 10%; OR = 0.80, 95% CI = 0.36 to 0.1.77) between 2 groups but a lower rate of permanent pacemaker implantation in the ViV-TAVI group (9% vs 15%; OR = 0.44, 95% CI = 0.24 to 0.81). This meta-analysis of nonrandomized studies with modest number of patients suggested that ViV-TAVI had similar 30-day survival compared with redo-SAVR for aortic BPV dysfunction., (Copyright © 2018 Elsevier Inc. All rights reserved.)

Renal dysfunction is a major risk factor for peripheral arterial disease (PAD). Infrapopliteal PAD is associated with more co-morbid conditions and worse prognosis than suprapopliteal PAD. Long-term outcomes of patients with renal dysfunction and popliteal or infrapopliteal PAD undergoing peripheral vascular intervention (PVI) are not well described. We retrospectively evaluated long-term outcomes in 726 patients undergoing infrapopliteal PVI categorized into 3 glomerular filtration rate (GFR)-based groups: GFR (≥60 ml/min/1.73 m(2)), GFR (<60 ml/min/1.73 m(2)), and those on dialysis. At mean follow-up of 36 ± 20 months, amputation rates were 3%, 5%, and 11% with mortality rates of 23%, 36%, and 56% in normal renal function, chronic kidney disease (adjusted odds ratio [OR] for amputation 1.75, 95% CI 0.73 to 4.21; adjusted OR for mortality 1.53, 95% CI 1.05 to 2.23, p = 0.028), and dialysis (adjusted OR for amputation 2.43, 95% CI 0.84 to 7.02, p = 0.100; adjusted OR for mortality 4.51, 95% CI 2.46 to 8.26, p <0.0001) groups, respectively. Repeat revascularization was similar in all 3 groups at roughly 25%. In conclusion, chronic kidney disease and dialysis were associated with increased major amputations and mortality in patients who received PVI for popliteal and infrapopliteal PAD., (Copyright © 2016 Elsevier Inc. All rights reserved.)